Champions Oncology, Inc. (NASDAQ:CSBR - Get Free Report) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.46 and traded as low as $5.90. Champions Oncology shares last traded at $6.1990, with a volume of 6,648 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings cut Champions Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Sell".
View Our Latest Stock Analysis on CSBR
Champions Oncology Stock Up 4.0%
The company has a fifty day moving average of $5.95 and a two-hundred day moving average of $6.46. The stock has a market capitalization of $86.10 million, a price-to-earnings ratio of -38.74 and a beta of 0.43.
Institutional Investors Weigh In On Champions Oncology
Several hedge funds have recently modified their holdings of the stock. Mink Brook Asset Management LLC acquired a new stake in shares of Champions Oncology during the fourth quarter worth $555,000. Essex Investment Management Co. LLC acquired a new stake in shares of Champions Oncology during the fourth quarter worth $126,000. Vanguard Group Inc. lifted its holdings in shares of Champions Oncology by 1.9% during the third quarter. Vanguard Group Inc. now owns 333,258 shares of the biotechnology company's stock worth $2,158,000 after purchasing an additional 6,229 shares during the period. XTX Topco Ltd acquired a new stake in shares of Champions Oncology during the second quarter worth $103,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 8,814 shares during the period. 41.30% of the stock is owned by institutional investors and hedge funds.
About Champions Oncology
(
Get Free Report)
Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Champions Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Champions Oncology wasn't on the list.
While Champions Oncology currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
SpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026.
These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
